"Ophthalmic Solutions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.
| Descriptor ID |
D009883
|
| MeSH Number(s) |
D26.776.708.645 D27.505.954.578.645 D27.720.752.608
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ophthalmic Solutions".
Below are MeSH descriptors whose meaning is more specific than "Ophthalmic Solutions".
This graph shows the total number of publications written about "Ophthalmic Solutions" by people in this website by year, and whether "Ophthalmic Solutions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 3 | 4 |
| 2012 | 1 | 3 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 3 | 4 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 4 | 4 |
| 2019 | 2 | 5 | 7 |
| 2020 | 2 | 10 | 12 |
| 2021 | 2 | 7 | 9 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ophthalmic Solutions" by people in Profiles.
-
Wakabayashi T, Mansour HA, Abishek RM, Sridhar J, Cohen MN, Xu D, Deaner J, Yonekawa Y, Hsu J, Kuriyan AE. Google Search Trends to assess public interest in and concern about Vuity for treating presbyopia. PLoS One. 2023; 18(10):e0293066.
-
Ivakhnitskaia E, Souboch V, Dallacasagrande V, Mizerska K, Souboch E, Sarkar J, Guaiquil VH, Tseng KY, Hirata H, Rosenblatt MI. Benzalkonium chloride, a common ophthalmic preservative, compromises rat corneal cold sensitive nerve activity. Ocul Surf. 2022 10; 26:88-96.
-
Shields CL, Paulose SA, Yaghy A, Dalvin LA, Constantinescu AB, Lally SE, Shields JA. Ocular Surface Squamous Neoplasia Managed With Primary Interferon a2b: A Comparative Analysis of 212 Tumors in Smokers Versus Nonsmokers. Cornea. 2021 Nov 01; 40(11):1387-1394.
-
Janeczko P, Norris MR, Bielory L. Assessment of receptor affinities of ophthalmic and systemic agents in dry eye disease. Curr Opin Allergy Clin Immunol. 2021 10 01; 21(5):480-485.
-
Shiuey EJ, Mehran NA, Ustaoglu M, Zhang Q, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Lee D. The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes. Graefes Arch Clin Exp Ophthalmol. 2022 Mar; 260(3):967-974.
-
Arbabi A, Bao X, Shalaby WS, Razeghinejad R. Systemic side effects of glaucoma medications. Clin Exp Optom. 2022 03; 105(2):157-165.
-
Shukla AG, Muir KW, Myers JS. Pivoting from Traditional Eye Drop Administration. Ophthalmol Glaucoma. 2021 Sep-Oct; 4(5):437-439.
-
McLaurin EB, Evans D, Repke CS, Sato MA, Gomes PJ, Reilly E, Blender N, Silva FQ, Vantipalli S, Metzinger JL, Gibson A, Goldstein MH. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. Am J Ophthalmol. 2021 09; 229:288-300.
-
Obeid A, Hsu J, Ehmann D, Gao X, Sridhar J, Chiang A, Park CH, Ho AC. TOPICAL DORZOLAMIDE-TIMOLOL WITH INTRAVITREOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY. Retin Cases Brief Rep. 2021 Mar 01; 15(2):120-126.
-
Shields CL, Constantinescu AB, Paulose SA, Yaghy A, Dalvin LA, Shields JA, Lally SE. Primary treatment of ocular surface squamous neoplasia with topical interferon alpha-2b: Comparative analysis of outcomes based on original tumor configuration. Indian J Ophthalmol. 2021 03; 69(3):563-567.